Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic

This Viewpoint considers whether the shift away from private investment toward government funding of drug and vaccine development and commercialization during the COVID-19 pandemic is sustainable.

Journal of the American Medical Association